Abcellera Biologics Incis A Biotechnology Company Based In Vancouverbritish Columbiaspecializing In Antibody Discovery And Developmentfounded In 2012 As A Spin Off From The University Of British Columbiaabcellera Operates As A Contract Research Organizationcrofocused On Translating Natural Immune Responses Into Therapeutic Solutionsthe Company Has Developed A Proprietary Platform That Utilizes Microfluidicssingle Cell Screeningnext Generation Dna Sequencingand Machine Learning To Identify And Analyze Antibodies Abcellera Offers Services In Antibody Discovery And Drug Development Partnershipsproviding Comprehensive Support From Target Validation To Clinical Trialsthe Company Has Established Key Partnershipsincluding Collaborations With Eli Lilly And Pfizerand Has Received Funding From Darpa For Its Pandemic Response Initiativeswith A Commitment To Addressing Complex Therapeutic Challengesabcellera Is Also Advancing An Internal Pipeline Targeting Cancermetabolic Disordersand Autoimmune Diseases
